Glucotrack and onetwo analytics present positive final results of first-in-human study for continuous blood glucose monitor at american diabetes association's 85th scientific sessions

Rutherford, n.j. and stockholm, june 25, 2025 (globe newswire) -- glucotrack, inc. (nasdaq: gctk), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results from its completed first-in-human clinical study presented at the american diabetes association's (ada) 85th scientific sessions, which took place june 20-23, 2025, in chicago.
GCTK Ratings Summary
GCTK Quant Ranking